Abstract

Cancer cachexia is a debilitating condition seen frequently in patients with pancreatic ductal adenocarcinoma (PDAC). The underlying mechanisms driving cancer cachexia are not fully understood but are related, at least in part, to the immune response to the tumor both locally and systemically. We hypothesize that there are unique differences in cytokine levels in the tumor microenvironment and systemic circulation between PDAC tumors and that these varying profiles affect the degree of cancer cachexia observed. Patient demographics, operative factors, oncologic factors, and perioperative data were collected for the two patients in the patient derived xenograft (PDX) model. Human pancreatic cancer PDX were created by implanting fresh surgical pancreatic cancer tissues directly into immunodeficient mice. At PDX end point, mouse tumor, spleen and muscle tissues were collected and weighed, muscle atrophy related gene expression measured, and tumor and splenic soluble proteins were analyzed. PDX models were created from surgically resected patients who presented with different degrees of cachexia. Tumor free body weight and triceps surae weight differed significantly between the PDX models and control (P < 0.05). Both PDX groups had increased atrophy related gene expression in muscle compared to control (FoxO1, Socs3, STAT3, Acvr2b, Atrogin-1, MuRF1; P < 0.05). Significant differences were noted in splenic soluble protein concentrations in 14 of 15 detected proteins in tumor bearing mice when compared to controls. Eight splenic soluble proteins were significantly different between PDX groups (P < 0.05). Tumor soluble proteins were significantly different between the two PDX groups in 15 of 24 detected proteins (P < 0.05). PDX models preserve the cachectic heterogeneity found in patients and are associated with unique cytokine profiles in both the spleen and tumor between different PDX. These data support the use of PDX as a strategy to study soluble cachexia protein markers and also further efforts to elucidate which cytokines are most related to cachexia in order to provide potential targets for immunotherapy.

Highlights

  • Pancreatic cancer is a lethal malignancy with overall 7% five-year survival

  • Xenografts were created from patients and expanded in vivo using our patient derived xenograft (PDX) model described in methods

  • The objective of this work was to better understand cytokine profiles in the tumor microenvironment and systemic circulation and how they related to cachexia in a representative model of human pancreatic adenocarcinoma

Read more

Summary

Introduction

Pancreatic cancer is a lethal malignancy with overall 7% five-year survival. It is projected to become the second leading cause of cancer related deaths by 2030 [1]. While no universal definition or classification system of cancer cachexia is routinely used in clinical practice, it is characterized by unintentional weight loss due to wasting of muscle and adipose tissue. It is a multifactorial, systemic syndrome associated with progressive functional decline, decreased quality of life, limitations in treatment options, and subsequent worse survival [5,6,7,8]. The degree to which disease burden correlates with cancer cachexia varies widely and suggests that there may be unappreciated underlying cellular and molecular mechanisms contributing to this process [9].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call